0MV5 Stock Chart & Stats
€69.92
-€2.26(-4.51%)
At close: 4:00 PM EST
€69.92
-€2.26(-4.51%)
Day’s Range― - ―
52-Week Range€56.24 - €74.28
Previous CloseN/A
Volume78.68K
Average Volume (3M)139.56K
Market Cap
€12.00B
Enterprise Value€17.48K
Total Cash (Recent Filing)€618.00M
Total Debt (Recent Filing)€5.47B
Price to Earnings (P/E)22.7
Beta1.05
Next Earnings
Mar 02, 2027EPS Estimate
1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.00
Shares Outstanding176,000,000
10 Day Avg. Volume56,807
30 Day Avg. Volume139,557
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.17
Price to Sales (P/S)1.54
P/FCF Ratio20.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€70.83Price Target Upside1.31% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)3.9
Revenue Forecast (FY)€7.60B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA 36.7% revenue jump in 2025 reflects durable demand for testing services across end markets. Sustained top‑line growth supports scale economics, funds reinvestment in labs and technology, and underpins long‑term contract wins and recurring client relationships across regulated sectors.
Business Model & Recurring RevenueEurofins’ fee‑for‑service model with high‑volume routine assays and higher‑value specialized projects creates recurring, contract‑driven revenue. Regulatory monitoring and production QC create repeatable demand, improving predictability of cash flows and resilience to single‑market shocks.
Scale & Technical CapabilitiesA large lab network and broad service set create a durable competitive advantage: high barriers to entry, ability to service global clients, and cross‑sell technical offerings. Scale supports operational efficiency, standardized processes, and long‑term client retention across industries.
Bears Say
Rising LeverageA material jump in leverage reduces financial flexibility and raises refinancing and interest‑burden risk over the medium term. With higher debt, the firm has less capacity for opportunistic M&A, increased sensitivity to slower cash flow, and reduced buffer against cyclical downturns.
Weaker Free Cash FlowDeclining FCF and lower cash conversion indicate rising capex or working‑capital pressure that can constrain deleveraging and reinvestment. Weaker cash generation reduces capacity to pay down debt, invest in lab capacity or innovation, and maintain operational cushioning over multiple quarters.
Margin Volatility & Earnings QualityLarge swings in gross margin and a falling net margin (from ~11.6% to ~6.5%) signal earnings volatility and potential one‑offs or cost pressures. Persistent margin instability complicates forecasting, weakens sustainable profitability, and undermines reliable free‑cash generation for strategic priorities.
Eurofins Scientific News
0MV5 FAQ
What was Eurofins Scientific’s price range in the past 12 months?
Eurofins Scientific lowest share price was €56.24 and its highest was €74.28 in the past 12 months.
What is Eurofins Scientific’s market cap?
Eurofins Scientific’s market cap is €12.00B.
When is Eurofins Scientific’s upcoming earnings report date?
Eurofins Scientific’s upcoming earnings report date is Mar 02, 2027 which is in 205 days.
How were Eurofins Scientific’s earnings last quarter?
Eurofins Scientific released its earnings results on Jul 23, 2026. The company reported €2.09 earnings per share for the quarter, beating the consensus estimate of €1.91 by €0.18.
Is Eurofins Scientific overvalued?
According to Wall Street analysts Eurofins Scientific’s price is currently Undervalued.
Does Eurofins Scientific pay dividends?
Eurofins Scientific does not currently pay dividends.
What is Eurofins Scientific’s EPS estimate?
Eurofins Scientific’s EPS estimate is 1.62.
How many shares outstanding does Eurofins Scientific have?
Eurofins Scientific has 176,000,000 shares outstanding.
What happened to Eurofins Scientific’s price movement after its last earnings report?
Eurofins Scientific reported an EPS of €2.09 in its last earnings report, beating expectations of €1.91. Following the earnings report the stock price went down -5.95%.
Which hedge fund is a major shareholder of Eurofins Scientific?
Currently, no hedge funds are holding shares in GB:0MV5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
0MV5 Stock 12 Month Forecast
Average Price Target
€70.83
▲(1.31% Upside)







